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ABSTRACT: While a wide range of experimental and
commercial transfection reagents are currently available,
persistent problems remain regarding their suitability for
continued development. These include the transfection
efficiency for difficult-to-transfect cell types and the risks of
decreased cell viability that may arise from any transfection
that does occur. Therefore, research is now turning toward
alternative molecules that improve the toxicity profile of the
gene delivery vector (GDV), while maintaining the trans-
fection efficiency. Among them, cell-penetrating peptides, such
as octa-arginine, have shown significant potential as GDVs.
Their pharmacokinetic and pharmacodynamic properties can be enhanced through peptidomimetic conversion, whereby a
peptide is modified into a synthetic analogue that mimics its structure and/or function, but whose backbone is not solely based
on α-amino acids. Using this technology, novel peptidomimetics were developed by co- and postpolymerization
functionalization of substituted ethylene oxides, producing poly(ethylene glycol) (PEG)-based peptidomimetics termed
“PEGtides”. Specifically, a PEGtide of the poly(α-amino acid) oligo-arginine [poly(glycidylguanidine)] was assessed for its
ability to complex and deliver a small interfering ribonucleic acid (siRNA) using a range of cell assays and high-content analysis.
PEGtide−siRNA demonstrated significantly increased internalization and gene inhibition over 24 h in Calu-3 pulmonary
epithelial cells compared to commercial controls and octa-arginine-treated samples, with no evidence of toxicity. Furthermore,
PEGtide−siRNA nanocomplexes can provide significant levels of gene inhibition in “difficult-to-transfect” mouse embryonic
hypothalamic (mHypo N41) cells. Overall, the usefulness of this novel PEGtide for gene delivery was clearly demonstrated,
establishing it as a promising candidate for continued translational research.
■ INTRODUCTION
Since its discovery, short interfering RNA (siRNA) has been
under near-constant development as a potential therapy for a
wide range of conditions.1,2 Initially, research was focused on the
more obvious targets of diseases with an underlying genetic
cause such as cystic fibrosis3,4 but has now expanded to more
varied targets such as dry eye disease, hepatitis B, and solid
tumors.1 Following initial setbacks in the clinical translation of
siRNA therapeutics, the technology is now experiencing a
resurgence with the first Food and Drug Administration (FDA)-
approved therapy, patisiran (Onpattro) by Alnylam, emerging
for hereditary amyloidogenic transthyretin amyloidosis and
several more now entering large-scale clinical trials.1,5 However,
a major issue remaining in developing siRNA therapeutic targets
is the lack of suitable gene delivery vectors (GDVs) for most
target organs. Poor cell uptake, toxicity, and immune cell
activation are common issues reported among many synthetic
vectors that otherwise display a promising level of gene
inhibition.2
To avoid some issues observed concerning the administration
of compounds that the body views as foreign, cell-penetrating
peptides (CPPs) have been investigated as siRNA GDVs for a
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range of cell types/organs.6 The oligo-arginine peptides,
specifically octa-arginine (R8) and nona-arginine (R9) peptides,
were identified as early candidates for the delivery of siRNA.
From their preliminary studies, it was found that oligo-arginine−
siRNA nanoparticles were capable of inducing gene knockdown
to levels similar to or better than those observed with the
reference CPP TAT.7
However, despite significant achievements in the field of
peptide therapeutics, peptide-based candidates may have some
shortcomings in clinical development.8 To address some of
these issues, efforts have led to the development of a class of
molecules with peptide-like functions, known as “peptidomi-
metics”. A peptidomimetic is a generic term describing a
molecule that displays the biological activity of a parent peptide
while being structurally different.9−11 It can mimic a peptide
primary structure through the use of amide bond isosteres and/
or alteration of the native peptide backbone, including retro-
inverso modification, chain extension, cyclization, or heter-
oatom incorporation.11−13 This has been successfully applied to
a range of clinical applications, including the development and
optimization of antimicrobial peptides and cell-binding
motifs.10,14,15 Recently, work has also been undertaken to utilize
the potential of the peptidomimetic technology in the delivery of
biological macromolecules to generate targeted gene delivery
vectors16 or to improve the uptake ability and metabolic stability
of preexisting CPPs.17
In addition to the peptidomimetic conversion, the mod-
ification of peptides and proteins with poly(ethylene glycol)
(PEG) chains, termed pegylation, is another archetypal
technique of structural adaptation for polyamide-based
therapeutics.21 However, the combination of these two
approaches has not been attempted to date. Therefore, the
synthesis of a novel PEG-based oligo-arginine peptidomimetic
and evaluation of its capacity to complex and deliver siRNA are
reported therein. This peptidomimetic would combine the
previously described ability of polyarginines to effectively deliver
siRNA with the improved safety profiles that have long been
associated with PEGylation.18,19 Specifically, PEG chains
functionalized with groups resembling amino acid side chains
and separated by an equal number of bonds compared to that in
a peptide (Figure 1) were formed by a co- and postpolymeriza-
tion functionalization approach. These hybrid structures of PEG
and peptides, termed “PEGtides”, are therefore different from
the PEGtide dendrons that alternate monodisperse non-
functionalized PEG chains and dipeptide Lys-β-Ala motifs.20
Accordingly, a substituted oxirane was polymerized to form a
functionalized PEG, which was modified to produce the oligo-
arginine mimetic poly(glycidylguanidine) (PGG, 4; Scheme 1).
This CPP PEGtide, named thereafter PEGtide, was then tested
for its ability to form nanocomplexes with siRNA, as well as to
promote uptake and gene inhibition versus commercial controls.
Its safety profile was also established. This allowed for the rapid
evaluation of this novel molecule’s future potential as a
successful siRNA delivery vector.
■ RESULTS
PEGtide Synthesis. The poly(glycidylguanidine) (4) was
produced in four synthetic steps in 16% overall yield (Scheme
1). Reactions were monitored by 1H NMR and shown to be
quantitative. The purification of the last intermediate was
performed by size exclusion chromatography (SEC), and the
final product (PEGtide) was analyzed by 1H NMR and matrix-
assisted laser desorption ionization time-of-flight mass spec-
trometry (MALDI-TOF MS).
The PEG backbone of this peptidomimetic was produced by
anionic ring-opening polymerization of tert-butyl N-(2-
oxiranylmethyl)carbamate, using potassium hydroxide as the
initiator. Polymerization in the bulk monomer at 150 °C
resulted in its complete conversion as well as the formation of
tert-butylated amine repeating units by thermal decomposition
of the t-Butyloxycarbonyl (Boc) group.21 The latter was then
removed from the polymer by treatment with trifluoroacetic
acid. The deprotected primary amines were, in turn, reacted with
N,N′-di-Boc-1H-pyrazole-1-carboxamidine, resulting in the
guanylation of most repeating units. After SEC purification of
this ultimate intermediate, the final deprotection of the
guanidine groups was performed by treatment with trifluoro-
acetic acid, yielding poly(glycidylguanidine) (PGG). MALDI-
TOF MS analysis was performed to characterize this product.
The spectrum displayed main and fragmentation peak series,
separated by 16 mass units, characteristic of PEG,22,23 with
molecular weight distributions based on a glycidylguanidine
repeating unit. It also showed the presence of tert-butylated
amine and free amine repeating units and a degree of
polymerization for PGG ranging from 3 to 13 (Figure 2).
Accordingly, most PEGtide chains formed by this approach
display the minimum net cationic charge required for the
biological activity of the parent peptide. The polymerization of 1
g of monomer yielded 136 mg of PEGtide. The fractionation of
this polymer into smaller ranges of repeating units was
attempted by high-performance liquid chromatography
(HPLC) (ion exchange chromatography, reversed phase (RP),
SEC) but remained impracticable, so the polydisperse PEGtide
(4) was tested for the transmembrane delivery of siRNA.
Size and ζ Potential of PEGtide−siRNA Nanoparticles.
Following complex formation by electrostatic interaction, the
physicochemical characteristics of the PEGtide−siRNA nano-
particles were assessed over a range of N/P ratios (Figure 3). It
was found that large nanoparticles of size approximately 540−
580 nm were observed at lower N/P ratios. The PEGtide−
siRNA nanoparticle size decreased to 298 nm at the highest
value of N/P = 30. Similarly, the polydispersity indices (PDIs)
also demonstrated increasing homogeneity, with increasing N/P
ratios, with N/P = 15 and 30 both giving the lowest PDIs of 0.2.
The analysis of the surface charge revealed that PEGtide−siRNA
complexes formed increasingly cationic nanoparticles with
increasing N/P ratios. However, most of the nanoparticles
retained an overall anionic charge with fully cationic particles
only forming at N/P = 30.
Multiparameter Analysis of PEGtide−siRNA Nano-
particle Toxicity in Calu-3 Cells. High-throughput multi-
parameter methods were harnessed to rapidly screen for the
toxicity of PEGtide−siRNA nanoparticles in Calu-3 cells. The
nanoparticles were assessed using Calu-3 cells that were
Figure 1. General structures of peptides and side-chain-functionalized
poly(ethylene glycol)s as PEG-based peptidomimetics (Rn: variable
side chain; In: initiator).
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incubated with 100 nM siRNA per well over a range of
peptidomimetic/siRNA ratios for 24 h. Thereafter, cell viability
and nanoparticle-mediated toxicity were qualitatively and
quantitatively determined using the Cellomics Multiparameter
Cytotoxicity 3 kit and InCell 1000 Workstation software for
analysis.
The analysis of the data revealed that PEGtide−siRNA
nanoparticles remained well tolerated at all doses subsequently
shown to facilitate siRNA uptake, with significant decreases in
the cell number only observed at the higher N/P ratios of N/P =
60 and 100 (Figure 4A). However, these were only examined to
illustrate a dose response at very high doses.
The analysis of the cell death-associated characteristics was
also carried out. The examination of the changes observed in the
mitochondrial membrane potential (MMP) following nano-
particle administration yielded conflicting results (Figure 4B).
Some small MMP decreases in PEGtide−siRNA nanoparticle-
treated cells were observed at N/P = 12 and 60; however, there
appeared to be no correlation with the dose, thereby resulting in
no definite conclusions being drawn from this parameter. The
analysis of cytochrome c release from PEGtide−siRNA-treated
cells demonstrated no significant changes, regardless of the N/P
ratios applied, while a significant increase observed with the
positive control valinomycin confirmed that the assay
functioned as expected (Figure 4C). The examination of the
changes elicited in the plasma membrane permeability (PMP)
levels, however, resulted in much clearer indications of
cytotoxicity at higher doses (Figure 4D). Overall, the use of
PEGtide−siRNA nanoparticles was well tolerated and resulted
in no significant changes in PMP except at the higher N/P ratios
of 60 and 100.
Scheme 1. Synthetic Route to Poly(glycidylguanidine) (4), Starting from (±)-tert-Butyl N-(2-Oxiranylmethyl)carbamate
Figure 2.MALDI-TOF MS spectrum of poly(glycidylguanidine). The
molecular weight distributions of 677, 793, 908, 1023, 1138, 1253,
1368, 1483, and 1598 are from the main series, and the molecular
weight distributions of 661, 776, 892, 1007, 1122, 1237, 1352, 1467,
1582, and 1697 are from the fragmentation peak series. A version of this
spectrum labeled with exact masses is available in the Supporting
Information. Figure 3. (A) Particle size and polydispersity indices and (B) ζ
potential of PEGtide−siRNA nanoparticles at N/P ratios of 10−100
[±standard error of the mean (SEM), n = 5].
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Analysis of PEGtide−siRNA Nanoparticle Uptake in
Calu-3 Cells. The ability of the PEGtide−siRNA nanoparticles
to facilitate siRNA uptake by Calu-3 cells was assessed using
high-content analysis (HCA) and was compared to a bench-
mark, lipid-based, transfection reagent (RNAiFect). Calu-3 cells
were treated with fluorescein isothiocyanate (FITC)-tagged
siRNA−PEGtide nanoparticles using mimetic/siRNA ratios
ranging from 6 to 30. Thereafter, the cells were incubated for 2,
4, or 24 h prior to HCA quantification (Figure 5). At 2 h post-
treatment, there was no significant difference in nanoparticle
uptake between PEGtide−siRNA nanoparticles and RNAi-
Fect−siRNA nanoparticles. However, when the incubation time
was increased to 4 h, there were significantly higher levels of
nanoparticle uptake in the PEGtide−siRNA nanoparticles at N/
Figure 4. Quantitative high-content analysis (HCA) of valinomycin and MG132 positive controls and PEGtide−siRNA-nanoparticle-mediated
toxicity in Calu-3 cells measured at 24 h post-administration. (A) Cell count, (B) mitochondrial membrane potential (MMP), (C) cytochrome c (Cyt
c) release, and (D) plasma membrane permeability (PMP). Y axes represent the fluorescence intensity in arbitrary units (a.u.) (one-way analysis of
variance vs untreated cells, n = 3 ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001).
Figure 5. HCA 20× fused image analysis of PEGtide−siRNA uptake in Calu-3 cells 24 h post-transfection. The cells were treated with 100 nM of
FITC-tagged siRNA nanoparticles (green) and were subsequently stained for cell nuclei using Hoechst nuclear stain (blue) and cell membrane using
phalloidin−tetramethylrhodamine B isothiocyanate (TRITC) (red). (A) Untreated cells, (B) RNAiFect, (C) PEGtide N/P = 9, (D) expanded view of
PEGtide N/P = 15, and (E) quantitative HCA analysis of RNAiFect vs PEGtide−siRNA nanoparticle uptake in Calu-3 cells measured at 2, 4, and 24 h
post-administration (two-way ANOVA, n = 3 ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001).
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P = 15 and 30. The levels of PEGtide−siRNA nanoparticle
uptake continued to increase at 24 h post-treatment and led to
significantly higher levels of siRNA internalization than in
RNAiFect−siRNA-treated cells, at all N/P ratios, except 30,
where no significant difference between the two nanoparticles
was observed.
PEGtide−siRNA Nanoparticle Knockdown. To examine
the ability of PEGtide−siRNA nanoparticles to effect gene
knockdown, luciferase-expressing Calu-3 cells were transfected
with 100 nM antiluciferase siRNA for 24 h using optimal
conditions (Figure S8), and the results were analyzed (Figure
6A). At lower N/P ratios, there was no significant difference
between the peptidomimetic nanoparticles and RNAiFect-
treated samples. However, at N/P = 15 and 30, the knockdown
efficiency of peptidomimetic nanoparticles was significantly
higher than commercial controls with levels of knockdown as
high as 68.56± 12.85%. In contrast to its peptidomimetic, it was
found that octa-arginine transfection did not demonstrate
significant improvement in gene knockdown compared to
RNAiFect. Indeed, PEGtide−siRNA-mediated luciferase knock-
down was significantly higher than octa-arginine-transfected
samples at N/P = 30.
Finally, PEGtide−siRNA particles were also examined in the
N41 neuronal cell line to demonstrate the efficacy in a known
cell type that is commonly seen as difficult to transfect (Figure
6B). Using this cell line, it was observed that PEGtide−siRNA
was capable of significant levels of gene inhibition at N/P = 15
and 30 against negative controls. Furthermore, the levels of gene
knockdown were also comparable to those of the Lipofectamine
positive controls.
■ DISCUSSION
No standard method has been reported to convert a peptide into
a peptidomimetic. The structural modification can be from
conservative to extreme, but peptidomimetic transformations
tend to focus on the linear (polyamide) backbone of the peptide.
The latter is the target of degradative enzymes; consequently,
peptidomimetic conversions generally aim to replace the
polyamide chain by an analogous non-natural backbone. Many
peptidomimetic structures and approaches have been devel-
oped.24 However, these methods generally use synthetic
approaches reminiscent of peptide synthesis, following a
stepwise approach, where each amino acid derivative or
analogue is sequentially added to a growing chain. Therefore,
we have chosen an alternative strategy, based on a recently
introduced polymerization technique, which generates a linear
backbone analogous to the peptide’s polyamide chain. However,
polymer-based peptidomimetics of the oligo-arginine CPP were
successfully developed such as guanidinylated poly((oxa)-
norbornenes), polymethacrylamides, and oligo- and polycar-
bonates, as well as guanidinylated polymethacrylates,25−27 and
this technique has not yet been applied to PEG. Considering
that it was described as “the gold standard biocompatible
polymer for pharmaceutical and medical applications”,11 PEG
represents a highly attractive moiety to replace the polyamide
backbone of a peptide. The polymerization of functionalized
ethylene oxides and their subsequent modification can yield
PEG-based peptidomimetics of sequence-independent peptides.
We applied this peptidomimetic conversion here to a
homopoly(α-amino acid) representative of a class of peptidic
delivery agents to create a hybrid structure of PEG and a peptide
that we have termed a “PEGtide”. Consistent with the
polymerization technique used, the material obtained is a
polydisperse polymer. However, anionic ring-opening polymer-
ization, such as the one used here, is likely to provide better
control over the molecular weight distribution than cationic
ring-opening polymerization.14 It is noteworthy that the PEG-
based peptidomimetic PEGtide was produced from a racemic
substituted oxirane and is therefore optically inactive. This could
impact the ability of the PEGtide to complex a homochiral cargo
such as a siRNA. However, homochiral polymers themselves
would be associated with higher production costs. It should also
be considered that the biological activities of CPPs can be
independent of the stereochemistry of their constitutive amino
acids,28 although heterochiral CPPs and racemic mixtures of
these peptides are generally not used. Whether the use of
monodisperse and/or homochiral PEGtides provide even higher
transfection efficiencies will be investigated in the future. While
it will most likely be necessary to further refine either the
synthesis or purification for progression toward clinical
applications, the use of polydisperse transfection reagents is
more acceptable in an in vitro setting. Examples of these are
widely used in the fields of gene delivery and biomaterials (e.g.,
polyethylenimine and chitosan).29,30
When the PEGtide was complexed to siRNA, it was found to
form complexes in the nanorange with an increasing cationic
surface charge corresponding to an increasing N/P ratio, with a
fully cationic surface charge not observed until N/P > 15. This is
most likely because the full condensation of the siRNA is only
achieved at this point. This is consistent with the previously
described relationship between siRNA condensation and
increasing N/P ratio.31,32
Figure 6. (A) Percentage of luciferase knockdown in Calu-3 cells after
treatment with PEGtide−siRNA or octa-arginine siRNA nanoparticles
vs nontargeting controls using 100 nM of antiluciferase siRNA 24 h
post-transfection (two-way ANOVA, n = 3 ± SEM, † p < 0.05 †† p <
0.01, † vs RNAiFect, * vs octa-arginine). (B) Percentage of luciferase
knockdown in difficult-to-transfect N41 neuronal cells demonstrated
significant levels of knockdown that were comparable to those in
commercial controls (one-way ANOVA, n = 3 ± SEM, * p < 0.05, ** p
< 0.01, significance vs nontargeting controls).
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Overall, size distribution was similar to current CPP-based
transfection platforms (e.g., the PepFect system)33,34 and other
peptidomimetic constructs.35 Considering the large size of these
particles relative to other nanoparticles, it is most likely a result
of the use of phosphate-buffered saline (PBS) as a dispersant in
complexation. This is indeed known to exert a significant
influence on the size and surface charge of siRNA nano-
complexes.36,37 Furthermore, the lower charge density and PEG
backbone of the PEGtide itself are also known to exert an effect
on nanoparticle size and charge. Recent studies involving a range
of PEGylated polymers have highlighted the effect that PEG
molecular weights and grafting densities can have on particle size
and ζ potential.38 Specifically, Moore et al. also demonstrated
that varying the level of cationic grafting to a PEG backbone can
result in nucleic acid nanoparticle sizes ranging from 200 to 500
nm.39 Furthermore, decreases in ζ potentials following
PEGylation of CPPs have also been reported.40 Finally, there
are numerous reports indicating that incubation in serum will
have dramatic effects on particle size and charge. Specifically,
work by Kummitha et al.41 and Strojan et al.42 using a range of
particle types found that size and polydispersity dramatically
increase following exposure to serum. However, considering the
high levels of gene inhibition observed in this study, serum-
PEGtide interactions did not pose an insurmountable obstacle
to cell endocytosis.
Using a multiparameter HCA approach, PEGtide−siRNA
nanoparticles were found to be well tolerated with no indications
of toxicity up to N/P = 60 and 100 using 100 nM of siRNA. At
these N/P ratios, the cell numbers were significantly reduced,
and PMP was found to be significantly enhanced as was
previously reported at cytotoxic levels using this approach.36
While the cell numbers were found to be dose-dependent in a
clear fashion, the additional cytotoxic parameters provided
additional details on the nature of the cytotoxic mechanism in
action. This was most evident in the staining for cytochrome c
release. While treatment with both valinomycin and MG132
resulted in significant decreases in the cell number, only
treatment with valinomycin resulted in significant release of
cytochrome c. Although both positive controls are known to
induce apoptosis via cytochrome c release and subsequent
caspase cascade,43 it is also possible that the more potent
MG132 is also inducing cell death via caspase-independent cell
death such as autophagy. This mode of cell death has been found
to occur independently of caspase release,44 although there is a
large amount of cross-talk between the two mechanisms. The
safety profile of these PEGtides was further clarified compared to
previously established toxicities of commercial gene delivery
vectors. Specifically, studies by Breunig et al. demonstrated that
following lipofectamine use, at comparable nucleic acid
concentrations to those used in this study, decreases in cell
viability of 12−47% were observed.45 Furthermore, toxicity
profiles determined by the PEGtide approach described here
represent an improvement on previous efforts by the authors
with octa-argine grafting, which demonstrated decreases in
viability of 15−40%.46
To analyze a large array of time points and doses, HCA
methods were employed, similar to those previously described in
industrial and research applications.36 When assessed for uptake
into Calu-3 cells, PEGtide−siRNA nanoparticles did not
demonstrate any significant difference from RNAiFect until 4
h post-treatment. This lower rate of uptake for anionic particles
would also be in keeping with the difficulties expected from
anionic or weakly cationic particles interacting with the
negatively charged cell membrane. The polydispersity of some
of the lower N/P ratios results in some uncertainty regarding
their behavior; most likely, there is a subpopulation of smaller
particles that possess a size and charge amenable to endocytosis.
While the ζ potential for these N/P ratios is negative, studies
have found that negatively charged particles can internalize via
clathrin-mediated endocytosis.47
Specifically, at 4 h post-treatment, the only PEGtide−siRNA
nanoparticles that had significantly higher levels of siRNA
uptake compared to RNAiFect−siRNA nanoparticles were the
most compact and cationic ones (N/Ps = 15 and 30). However,
when tested at 24 h post-treatment and N/P ratios ranging from
6 to 15, the levels of siRNA uptake were significantly higher with
PEGtide than with RNAiFect. Considering the PEGtide−
siRNA nanoparticle size and surface charge, it is likely that they
are transient aggregations based on their microenvironment but
that dispersion and subsequent transfection ultimately occur
(albeit at a much reduced rate). This was found to be the case
using other nanoparticle systems and has even been used as a
strategy for targeting the lungs.48,49
Interestingly, a decrease in uptake levels was also observed
from 4 to 24 h in PEGtide−siRNA samples at N/P = 30. Since
these nanoparticles were observed to be internalized at the
highest rate, this drop was likely a result of faster overall cycling
through the cell trafficking machinery. The result is either
exocytosis via egress of the PEGtide−siRNA from late
endosomes/lysosomes (≅70% of the internalized siRNA)50 or
final degradation in the lysosome. This was previously found to
be the case for 99% of delivered particles that are not ejected51
and would explain the apparent drop in the number of
internalized PEGtide−siRNA particles.
The PEGtide delivery of siRNA to Calu-3 cells resulted in the
efficient knockdown of ∼70% at N/P = 30. These levels of
knockdown were significantly higher than both RNAiFect
commercial controls and luciferase knockdown obtained using
the same N/P ratio of traditional octa-arginine. When
comparing against the earlier uptake experiments, we note that
while uptake was faster overall at N/P = 30, there was no
significant difference between N/P = 15 and 30. This is reflected
in the gene knockdown data described and we contend that this
is most likely a result of all available RNA-induced silencing
complex machinery becoming saturated or approaching a point
of saturation at the 24 h mark.
Furthermore, PEGtide delivery of siRNA provided significant
levels of gene knockdown in the “hard-to-transfect” N41
neuronal cell line at a level approaching those achieved with
commercially available Lipofectamine 2000 (Lf2000). It is also
worth considering that the PEGtide−siRNA system described
here is relatively low in molecular weight, simple in structure,
and can be formed in a four-step reaction procedure from
relatively inexpensive reagents. This should allow for successful
future scale-up and testing in more complex in vitro and in vivo
models.
■ CONCLUSIONS
With siRNA now achieving FDA approval for certain
indications, it remains imperative that there are appropriate
carriers for safe and efficient delivery for a range of diseases and
organs. The PEGtide system described in this paper has
demonstrated a strong capability for nanoparticle formation
combined with a low-toxicity profile and high levels of gene
inhibition. It also represents a flexible system amenable to
applications that may encompass those that have been
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successfully implemented with CPPs, including the delivery of
proteins, liposomes, nanoparticles, and larger nucleic acids, such
as those used by the CRISPR/Cas-9 gene editing technology.
■ EXPERIMENTAL SECTION
Materials. The Fmoc-protected amino acids and Rink
Amide 4-methylbenzhydrylamine (MBHA) resin for peptide
synthesis were obtained from Novabiochem (Nottingham,
U.K.). Hexafluorophosphate azabenzotriazole tetramethyl
uronium (HATU) and N-methyl-2-pyrrolidone (NMP) were
purchased from ChemPep Inc. (Wellington, FL) and Bio-
Sciences (Dublin, Ireland), respectively. All other reagents and
solvents were sourced from Sigma-Aldrich (Dublin, Ireland)
except where indicated. siGENOME nontargeting siRNA #2 (5′
UAAGGCUAUGAAGAGAUAC 3′) was obtained from
Dharmacon (Lafayette, CO). The nontargeting sequence #2 is
nonspecific for human gene sequences and specific for firefly
luciferase using the Promega pGL3 cloning vector. AllStars
negative control siRNAwas obtained fromQiagen (Manchester,
U.K.). This siRNA has no homology to any known mammalian
gene and has been validated using Affymetrix GeneChip arrays
and a variety of cell-based assays. AllStars negative control
siRNA was also obtained from Qiagen with a fluorescein
isothiocyanate (FITC) modification for cell uptake studies.
General Experimental Methods. NMR spectra were
recorded using a Bruker Avance 400 spectrometer. MALDI-
TOF MS analysis was performed either on an AB Sciex 4800
MALDI-TOF/TOF (Cheshire, U.K.), using α-cyano-4-hy-
droxy-cinnamic acid as a matrix, or a Waters MALDI Q-Tof
Premier Mass Spectrometer (Milford, MA), using trans-2-[3-(4-
tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile as a
matrix.
Synthetic Procedures and Analytical Data. Octa-D-
Arginine Synthesis.
This peptide was assembled by standard solid-phase peptide
synthesis52 according to the Fmoc-tBu strategy53 with HATU/
N,N-diisopropylethylamine (DIEA) coupling chemistry in
NMP solvent. Single-coupling cycles, using a total 10-fold
excess of Fmoc-D-Arg(Pbf)-OH to resin-bound peptide, were
used. Assembly of the amino acid sequence, starting from a Rink
Amide MBHA resin, was carried out on a 100 μmol scale using a
433 Applied Biosystems automated peptide synthesizer
(Warrington, U.K.). The peptide was deprotected and released
from the resin by treatment with a cleavage cocktail consisting of
95% trifluoroacetic acid, 2.5% water, and 2.5% triisopropylsilane
for 4.5 h. The peptide was then precipitated from this solution
with diethyl ether, isolated by centrifugation, and washed three
times with diethyl ether. It was next air-dried, dissolved in
distilled water, and lyophilized.
Chromatographic analysis and purification were performed by
RP-HPLC using the Varian Galaxy HPLC (Walnut Creek, CA)
and PerSeptive BioSystems BioCad Sprint Perfusion Chroma-
tography HPLC (Warrington, U.K.), respectively, and Phenom-
enex Jupiter 5 μm C5 300 Å columns, 4.6 mm D × 250 mm L
analytical; 10 mmD× 250mm L semipreparative (Macclesfield,
U.K.). The mobile phase consisted of buffer A: 0.1%
trifluoroacetic acid (TFA) in water and buffer B: 0.1% TFA in
acetonitrile, with a linear gradient of 5−65%B in 30min at a flow
rate of 1 mL/min (analysis) or 4 mL/min (semipreparative).
UV single-wavelength detection was performed at 214 nm for
the BioCad Sprint, while the Varian Galaxy was equipped with a
photodiode array (PDA) detector operating from 190 to 950
nm. Purity was ascertained from the percent area of octa-
arginine relative to the total area of all UV-absorbing
components.
Analytical HPLC (C5): tR = 11.53 min, 89% purity.
MALDI-TOFMS (m/z) (α-cyano-4-hydroxy-cinnamic acid)
calcd for C48H100N33O8: 1266.843. Found: 1266.839.
Poly(glycidylguanidine) (PGG) Synthesis.
Poly(glycidyl tert-butylcarbamate) (1). Polymerization was
performed in the bulk monomer: tert-butyl N-(2-
oxiranylmethyl)carbamate (1.02 g, 5.9 mmol) was introduced
in a round-bottom flask maintained at 50 °C. Potassium
hydroxide (16.5 mg, 0.29 mmol) was added under nitrogen, and
the solution was stirred at 150 °C for 45 min. When the polymer
had begun to solidify, the polymerization was quenched by
adding methanol (2 mL), which was then removed under
vacuum, providing poly(glycidyl tert-butylcarbamate) in quanti-
tative yield.
1H NMR (400 MHz, CDCl3) δ = 3.84−2.98 (m, CH2O,
CH2N and CH, 6H), 1.37 (s, CH3 Boc, 9H), 1.20 (s, CH3 t-Bu,
3H).
The signal at 1.20 ppm is attributed to tert-butylated amine
repeating units (vide infra). Complete conversion of the
monomer is shown by the absence of signals at 2.59 and 2.40
ppm (CH2O).
Poly(glycidylamine) (2). Boc deprotection was carried out by
dissolving poly(glycidyl tert-butylcarbamate) (1.02 g, 5.9 mmol)
in a mixture of dichloromethane (3 mL) and trifluoroacetic acid
(3 mL). This solution was stirred in an open flask at 0 °C for 30
min, followed by 2 h at room temperature (RT). The solvent was
then removed by evaporation using a stream of nitrogen. The
residue was dissolved in water, and the solution was freeze-dried.
Poly(glycidylamine) was recovered as a yellow oil in quantitative
yield.
1H NMR (400 MHz, D2O) δ = 3.86−2.93 (m, CH, CH2O
and CH2N, 339 H), 1.08 (s, CH3 t-Bu, 9H).
The signal at 1.08 ppm is attributed to tert-butylated amine
repeating units. Successful deprotection was shown by the
reduction near to the baseline of the signal at 1.40 ppm (CH3
Boc).
Poly(glycidyl N,N′-di-Boc-guanidine) (3). To a solution of
poly(glycidylamine) (500 mg, 6.85 mmol) in dimethylforma-
mide (10 mL), N,N′-di-Boc-1H-pyrazole-1-carboxamidine (4.2
g, 13.7 mmol) and DIEA (4.76 mL, 27.4 mmol) were added.
The resulting yellow solution was stirred at room temperature
for 48 h. Water (50 mL) was then added, and the solution was
extracted with chloroform. The organic phase was subjected to
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size column chromatography (Sephadex LH 20 as the stationary
phase and methanol as the mobile phase); 400 mg (18%) of
product was recovered.
1H NMR (400 MHz, CDCl3) δ = 11.40 (bs, NH, 1H), 8.56
(bs, NH, 1H), 3.93−3.17 (m, CH, CH2O and CH2N, 8H), 1.40
(s, CH3, 18H).
Poly(glycidylguanidine) (PGG, 4). Boc deprotection was
carried out by dissolving polyglycidyl N,N′-di-Boc-guanidine
(400 mg, 1.23 mmol) in a mixture of dichloromethane (3 mL)
and trifluoroacetic acid (3 mL). This solution was stirred in an
open flask at 0 °C for 30 min, followed by 2 h at room
temperature. The solvent was then removed by evaporation
using a stream of nitrogen. The residue was dissolved in water,
and the solution was freeze-dried. Poly(glycidylguanidine) was
recovered as a yellow oil (136 mg, 95%).
1H NMR (400 MHz, D2O) δ = 3.90−2.96 (m, CH, CH2O
and CH2N, 294H), 1.09 (s, tBu, 9H).
The signal at 1.09 ppm is attributed to tert-butylated amine
repeating units. Successful deprotection was shown by the
disappearance of the signal at 1.40 ppm (CH3 Boc).
(MALDI-TOF MS) (m/z) (trans-2-[3-(4-tert-butylphenyl)-
2-methyl-2-propenylidene]-malononitrile):
(1) Repeating unit: calcd for C4H9N3O: 115.0746. Found
115.0714−115.0835.
(2) Main series: calcd fora C27H61N14O6: 677.4899;
C31H70N17O7: 792.5645; C35H79N20O8: 907.6391;
C39H88N23O9: 1022.7137; C43H97N26O10: 1137.7883;
C47H106N29O11: 1252.8629; C51H115N32O12: 1367.9375;
C55H124N35O13: 1483.0121; C59H133N39O14: 1598.0867.
Found 677.4373 [M]+, n = 4; 792.5162 [M]+, n = 5;
907.5981 [M]+, n = 6; 1022.6764 [M]+, n = 7; 1137.7567
[M]+, n = 8; 1252.8342 [M]+, n = 9; 1367.9177 [M]+, n =
10; 1482.9913 [M]+, n = 11; 1598.0627 [M]+, n = 12
(Figure 7).
(3) Fragmentation peak series (shifted 16 mass units from the
main series of the molecular weight distribution):23
Found 661.3962 [M− 16]+, n = 4; 776.4775 [M− 16]+, n
= 5; 891.5585 [M− 16]+, n = 6; 1006.6370 [M− 16]+, n =
7; 1121.7172 [M− 16]+, n = 8; 1236.7969 [M− 16]+, n =
9; 1351.8767 [M− 16]+, n = 10; 1466.9503 [M − 16]+, n
= 11; 1582.0428 [M − 16]+, n = 12; 1697.1379 [M −
16]+, n = 13.
Nanoparticle Formation and Physicochemical Data.
For octa-arginine and PEGtide−siRNA nanoparticle formation,
a weighed amount of polymer was diluted in PBS to the required
concentration of 1 mg/mL. Amine (N)-to-siRNA phosphate
(P) N/P ratios were calculated as previously described54 for
octa-arginine nanoparticles with equivalent masses of cationic
polymer used to make PEGtide−siRNA nanoparticles. Various
volumes of the cationic polymer solutions were then added to
the appropriate amount of 20 μM siRNA to give specific N/P
ratios and were diluted in PBS to a final concentration of 1 μM.
The polymer−siRNA solutions were then mixed gently with a
pipette to ensure homogeneity and were incubated at room
temperature for 20−30 min to allow nanoparticle formation.
The size distribution (mean diameter and polydispersity
index) and ζ potential of the siRNA nanoparticle dispersions
were measured by dynamic light scattering and laser Doppler
electrophoresis, respectively, using a Nano-ZS system (Nano
series; Malvern Instruments). This measured the mass
distribution of the particle size and the electrophoretic mobility
of the dispersed particles. Measurements were made at 25 °C
with a fixed angle of 137°. The sizes quoted are the z-average
means (dz) for the nanoparticle hydrodynamic diameter (nm).
Calculation of the ζ potential (mV) was performed using the
same instrument (from electrophoretic mobility). Following
complexation in PBS, the samples were diluted 1 in 50 with
deionized water prior to both procedures. This resulted in a final
ionic concentration of 2.74 mM NaCl, 0.054 mM KCl, 0.2 mM
Na2HPO4, and 0.04 mM KH2PO4. Both the size and ζ potential
were measured five times with an average of 15−20 subscans
taken in each measurement.
Multiparameter Cytotoxicity Study of Peptidomimet-
ic siRNA Nanoparticles in Calu-3 Cells. Twenty-four hours
prior to transfection, the cells were seeded at 3 × 104/well in a
96-well plate and were treated with 100 nM siRNA for 24 h. The
selected wells were treated with 120 μM valinomycin or 40 μM
carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132) for 24 h as
a positive control prior to analysis. Following incubation, the
cells were stained and fixed using the Cellomics Multiparameter
Cytotoxicity 3 kit (Thermo Scientific, Dublin, Ireland)
according to the manufacturer’s protocol. Briefly, the cells
were live-stained for mitochondrial membrane potential and
plasma membrane permeability. The cells were then fixed using
4% paraformaldehyde before staining withHoechst nuclear stain
and fluorescent antibody labeling for cytochrome c. Image
acquisition was determined using the InCell 1000 High Content
Analyzer (GE Healthcare, Buckinghamshire, U.K.). Four
random fields were viewed per well, and the various N/P ratios
were repeated in quadruplicate. The fluorescence intensity of
the dyes was monitored at the excitation and emission
wavelengths specific to each dye (i.e., 360 and 460 nm for
Hoechst, 480 and 535 nm for the permeability dye, 535 and 600
nm for themitochondrial membrane potential dye, and 646/674
nm for DyLight 649 conjugates).
The exposure times and hardware autofocus (HWAF) values
were varied between experiments to optimize the image quality.
Following acquisition of the images, the data were analyzed
using InCell 1000Workstation software and multitarget analysis
with a variety of settings for each of the parameters (Table S2).
All samples were run in quadruplicate, and the experiment was
repeated on three independent occasions. The commercial
transfection reagents for in vitro-only use were not assessed for
cytotoxicity. However, the various cytotoxic profiles for these
vectors were previously reported in several studies.55−57
siRNA Nanoparticle Uptake in Calu-3 Cells. Calu-3 cells
were seeded at 3 × 104 cells/well in a 96-well plate (Nunc) 24 h
before experiments. Nanoparticles were formed using electro-
static complexation in a final volume of 125 μL/well in serum-
free Dulbecco’s modified Eagle’s medium (DMEM) using 100
nM fluorescently tagged FITC−siRNA. Nanoparticles, or free
Figure 7. Proposed structure of the products formed under MALDI
conditions for the main series of the molecular weight distribution in
MS analysis.
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siRNA controls, were then incubated with the cells at 37 °C and
5% CO2 for 2, 4 and 24 h. The cells were washed with PBS and
fixed using 4% paraformaldehyde. The cells were then stained
for f-actin using phalloidin−TRITC and Hoechst nuclear stain.
Image analysis was achieved using the InCell 1000 High
Content Analyzer. Four random fields were viewed per well, and
the various treatments were repeated in quadruplicate. The
fluorescence intensity of the dyes was monitored at the
excitation and emission wavelengths specific to each dyei.e.,
360 and 460 nm for Hoechst, 480 and 535 nm for FITC−
siRNA, and 535 and 600 nm for phalloidin−TRITC. The
exposure times and hardware autofocus (HWAF) values were
varied to optimize the image quality. After acquisition of the
images, the data were analyzed using InCell 1000 Workstation
software andmultitarget analysis with various settings for each of
the parameters (Table S1). Specifically, minimum PEGtide−
siRNA nanocomplex diameters were measured using the
“organelle” function Workstation software and gated to include
only FITC-positive particles of a designated size that were inside
cells. These were proofed against negative controls to eliminate
background/artifact detection and total particles within cells
were counted and averaged. All samples were run in
quadruplicate, and the experiment was repeated on three
independent occasions.
siRNA Nanoparticle-Mediated Luciferase Knockdown
in Calu-3 Cells.Calu-3 cells were seeded at a density of 5 × 104
in 48-well plates 24 h prior to transfection. Thereafter, the cells
were first transfected with the luciferase control vector plasmid
(Promega, U.K.) and SuperFect transfection reagent (Qiagen,
Manchester, U.K.) at a dose of 0.75 μg of pDNA/3 μL of
SuperFect in 100 μL of serum-free DMEM per well for 4 h. The
cells were then washed three times with warm PBS and
transfected with antiluciferase PEGtide−siRNA nanoparticles
consisting of either antiluciferase siRNA or negative control
siRNA at 100 nM/well in 250 μL of serum-containing media,
followed by incubation for 24 h at 37 °C and 5% CO2.
Control transfections involving siRNA were carried out using
the cationic, lipid-based RNAiFect transfection vector (Qiagen,
Manchester, U.K.). siRNA (1 μg) was diluted to 100 μL in the
supplied Buffer EC-R and vortexed. The appropriate amount of
RNAiFect reagent was then added, and the solution was
vortexed again for 10 s. The samples were incubated at room
temperature for 20 min to allow complex formation. Thereafter,
the particles were diluted with serum-containing medium to a
final siRNA concentration of 100 nM before adding 250 μL of
the diluted solution to the cells.
Luciferase expression was assessed using the luciferase assay
system (Promega) and was read using a Wallac 1420 Multilabel
Counter (PerkinElmer). The protein expression in each sample
was examined using theMicro bicinchoninic acid (BCA) protein
assay kit (Pierce) according to the product instructions. All
samples were run in quadruplicate, and the experiment was
repeated on three independent occasions.
siRNA Nanoparticle-Mediated Luciferase Knockdown
inmHypoN41 Cells.Themouse embryonic hypothalamic cell
line mHypoE N41 was obtained from tebu-bio (Le Perray-en-
Yvelines, France) and was maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum in a humidified 37 °C incubator with 5% CO2. The cells
were seeded in 24-well plates at a density of 3.5 × 104 cells/well.
Silencing of an exogenous gene was assessed by measuring the
knockdown of the firefly luciferase gene. Cells were seeded in 24-
well plates for 1 day before transfection with the luciferase
reporter plasmid pGL3 luciferase (1 μg/well) complexed to
Lipofectamine 2000 (Invitrogen, Dublin, Ireland) (2.5 μL/μg
pDNA) for 4 h. Thereafter, the cells were washed twice with PBS
prior to siRNA transfection. siRNA was complexed with
PEGtide at varying N/P ratios (N/P = 6, 9, 12, 15, and 30)
and was incubated for 20−30 min, followed by dilution in
serum-free media without antibiotics. A final volume of media
on cells was 0.5 mL containing 100 nM siRNA per well.
Nonsilencing siRNA complexed to PEGtide at N/P = 30 was
used as a nontargeted control. After 24 h, the cells were lysed
with 1× lysis buffer (Promega, Southampton, U.K.). Next, the
lysates (20 μL) were assayed for the expression of luciferase by
adding 100 μL of luciferin (Promega) and measuring the
luminescence in a Junior LB 9059 luminometer (Promega). The
total protein levels in each sample were determined using the
BCA protein assay (Thermo Scientific, Dublin, Ireland) to allow
normalization of luciferase activity. The results were expressed
as the percent of gene expression relative to control samples.
The data are presented as mean ± SEM.
Control transfections involving siRNA were carried out using
the cationic lipid-based transfection reagent Lipofectamine 2000
(Lf2000). Lf2000·siRNA complexes were prepared according to
the manufacturer’s protocol. Briefly, the required volume of
Lf2000 was diluted in 50 μL of OptiMEM, mixed gently, and
incubated at RT for 5 min. siRNA was diluted in 50 μL of
OptiMEM and was combined with the diluted Lf2000, followed
by gentle mixing and incubation at RT for 20 min. One
microliter of Lf2000 was used per 20 pmol of siRNA.
Statistical Analysis. The results are expressed as the mean
± standard error of the mean (SEM) using GraphPad Prism 5
software. Two- and one-way analyses of variance (ANOVA)
were performed for differences between treatments with p-
values <0.05 considered significant, <0.01 very significant, and
<0.001 highly significant.
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■ ADDITIONAL NOTE
aThe main series of the molecular weight distribution can be
assigned to the structure shown in Figure 7, where the secondary
amine results from t-butylation during polymerization and the
primary amine results from incomplete guanylation during the
penultimate step. The vinyloxy and methoxy ends are
modifications formed by pyrolysis during MALDI analysis.22
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